Mauna Kea Technologies SAS

Research Mauna Kea Technologies SAS (ALMKT) on Bullrun: market cap EUR 30.39M, P/E 1.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 30.39M; P/E is 1.6.

Peer valuation comparison

Latest P/E is 1.64x versus a Healthcare sector median of 24.46x (93.3% below).

Latest P/E is 1.64x versus a France median of 15.25x (89.2% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 8.22MEUR 10.77M-EUR 3.89M75.3%0.06EUR 4.97MEUR 12.08M-EUR 4.82M
FY2024EUR 7.66M-EUR 10.40M-EUR 6.54M84.1%-0.16EUR 1.92MEUR 31.93M-EUR 24.39M
FY2023EUR 10.48M-EUR 3.73M-EUR 1.14M79.8%-0.08EUR 7.87MEUR 29.77M-EUR 17.28M
FY2022EUR 7.48M-EUR 11.18M-EUR 8.97M73.2%-0.25EUR 3.14MEUR 29.20M-EUR 19.92M
FY2021EUR 7.70M-EUR 13.45M-EUR 11.37M74.2%n/aEUR 11.87MEUR 28.70M-EUR 10.33M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24EUR 30.39M1.6n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About Mauna Kea Technologies SAS

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Mauna Kea Technologies SAS's market cap?

Mauna Kea Technologies SAS's market capitalization is EUR 30.39M.

What is Mauna Kea Technologies SAS's P/E ratio?

Mauna Kea Technologies SAS's price-to-earnings (P/E) ratio is 1.6.

What does Mauna Kea Technologies SAS do?

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate reactions as they occur, classify areas of uncertainty, guide surgical interventions, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.